Skip to main content

NEKTAR THERAPEUTICS

corporate_fare Company Profile

NEKTAR THERAPEUTICS

NKTR·NASDAQ·Life Sciences·CIK 0000906709

Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative medicines in immunotherapy. The company creates new immunomodulatory agents designed to selectively induce, amplify, attenuate, or prevent immune responses to achieve therapeutic outcomes. Nektar applies its understanding of immunology to identify and create drug candidates and advance them through preclinical and clinical development. Nektar's pipeline includes clinical-stage and preclinical-stage immunomodulatory agents targeting autoimmune diseases and cancer. For autoimmune diseases, examples include rezpegaldesleukin and NKTR-0165/0166, respectively. For cancer, an example is NKTR-255. The company invests in building and advancing its pipeline of drug candidates. Nektar's drug candidates modulate the immune system to target pathways critical in various serious diseases. In autoimmune diseases, the focus is on addressing immune system imbalances to restore self-tolerance mechanisms and achieve immune homeostasis. In oncology, the focus is on activating the immune system's natural tumor-fighting mechanisms. Many autoimmune diseases are caused by an immune system imbalance, where a failure of self-tolerance mechanisms leads to pathogenic T cells attacking healthy cells. Current systemic treatments, such as corticosteroids and anti-TNF agents, broadly suppress the immune system with severe side effects. Nektar aims to rebalance the immune system by increasing the function of regulatory T cells (Treg cells) to treat autoimmune and inflammatory disorders. Rezpegaldesleukin is a drug candidate that may address this underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases.

NEKTAR THERAPEUTICS (NASDAQ:NKTR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 30 items for NKTR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for NKTR spans 8-K, 10-Q, 424B5, DEFA14A.

Recent high-impact activity:

  • Nektar Posts $55.7M Q3 Loss, EPS of -$1.63 as Product Sales Reach $9.4M
  • Nektar Sinks 19% Despite Durable Hair Loss Data; Analysts See Positive Read-Through for Q32 Bio
  • Rezpegaldesleukin Demonstrates Durable Hair Regrowth Six Months After Treatment Cessation in Phase 2b Alopecia Areata Study
  • Rezpeg Shows Durable Response at One Year, Phase 3 AA Trial Set for Early 2027
  • Nektar Secures $90M Jury Verdict Against Eli Lilly in Rezpeg License Dispute

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$55.23M
Net Income
-$164.08M
Diluted EPS
-$9.73
Op. Cash Flow
-$208.51M
Free Cash Flow
-$208.68M
Gross Profit
$55.23M
Operating Income
-$140.1M
Cash & Equivalents
$15.12M
Debt / Equity
0.00×
Net Margin
-297.1%
Shares Outstanding
20.38M sh
Source: 10-K · filed 2026-03-12 · accession 0001193125-26-104547

Short Interest & Short Volume

10.26 days to cover

FINRA reported short interest of 6,766,027 shares in NKTR as of the October 30, 2026 settlement, a 3.3% decrease from the prior period — about 10.3 days to cover at its recent average daily volume. On November 19, 2026, 63.7% of NKTR volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)6,766,027 shares as of October 30, 2026
Change vs prior period▼ 3.3%
Days to cover10.26 at avg daily volume of 659,707
Daily short volume (FINRA facilities)63.7% of 391,929 shares on November 19, 2026
5-day average short volume55.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for NKTR, detected from its recent SEC filings · based on capital-structure filings through 2026-06-05.

Share Incentive Plan Expansion Approved · Potential Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with N →
$30.32 -6.84% today
52-week range · as of 2026-10-01 $30.32 – $109
Market cap
$1.04B
Volume
814.1K (1.1× avg)
3-mo avg 749.8K
Live data · 2026-11-20 20:49 UTC · Market open

show_chartPrice Chart

Loading chart...

feed NKTR - Latest Insights

NKTR
Nov 12, 2026, 4:16 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $37.25
Real-time Price: $30.32 info
Change: -$6.93 (-19%) info
Market Cap: $1.037B info
NKTR
Oct 01, 2026, 11:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $48.58
Real-time Price: $30.32 info
Change: -$18.26 (-38%) info
Market Cap: $1.037B info
NKTR
Oct 01, 2026, 7:57 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $60.70
Real-time Price: $30.32 info
Change: -$30.39 (-50%) info
Market Cap: $1.037B info
NKTR
Oct 01, 2026, 7:31 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $60.50
Real-time Price: $30.32 info
Change: -$30.19 (-50%) info
Market Cap: $1.037B info
NKTR
Sep 25, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $62.26
Real-time Price: $30.32 info
Change: -$31.94 (-51%) info
Market Cap: $1.037B info
NKTR
Sep 22, 2026, 3:17 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $61.22
Real-time Price: $30.32 info
Change: -$30.90 (-50%) info
Market Cap: $1.037B info
NKTR
Aug 13, 2026, 6:57 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $74.97
Real-time Price: $30.32 info
Change: -$44.66 (-60%) info
Market Cap: $1.037B info
NKTR
Aug 13, 2026, 4:26 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $76.30
Real-time Price: $30.32 info
Change: -$45.99 (-60%) info
Market Cap: $1.037B info
NKTR
Aug 13, 2026, 4:25 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $76.30
Real-time Price: $30.32 info
Change: -$45.99 (-60%) info
Market Cap: $1.037B info
NKTR
Jun 05, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $57.32
Real-time Price: $30.32 info
Change: -$27.01 (-47%) info
Market Cap: $1.037B info
NKTR
May 08, 2026, 5:23 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $82.41
Real-time Price: $30.32 info
Change: -$52.10 (-63%) info
Market Cap: $1.037B info
NKTR
May 08, 2026, 5:11 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $82.41
Real-time Price: $30.32 info
Change: -$52.10 (-63%) info
Market Cap: $1.037B info
NKTR
May 07, 2026, 6:20 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $85.99
Real-time Price: $30.32 info
Change: -$55.68 (-65%) info
Market Cap: $1.037B info
NKTR
May 07, 2026, 4:31 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $82.89
Real-time Price: $30.32 info
Change: -$52.57 (-63%) info
Market Cap: $1.037B info
NKTR
May 07, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $82.89
Real-time Price: $30.32 info
Change: -$52.57 (-63%) info
Market Cap: $1.037B info
NKTR
Apr 24, 2026, 4:16 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $91.68
Real-time Price: $30.32 info
Change: -$61.37 (-67%) info
Market Cap: $1.037B info
NKTR
Apr 23, 2026, 6:06 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $92.80
Real-time Price: $30.32 info
Change: -$62.49 (-67%) info
Market Cap: $1.037B info
NKTR
Apr 23, 2026, 6:02 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $92.80
Real-time Price: $30.32 info
Change: -$62.49 (-67%) info
Market Cap: $1.037B info
NKTR
Apr 21, 2026, 9:31 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $98.48
Real-time Price: $30.32 info
Change: -$68.17 (-69%) info
Market Cap: $1.037B info
NKTR
Apr 20, 2026, 5:00 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $101.85
Real-time Price: $30.32 info
Change: -$71.53 (-70%) info
Market Cap: $1.037B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets